GT Biopharma Inc. (GTBP)
GT Biopharma Announces IND Submission for GTB-5550TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma Announces IND Submission for GTB-5550TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical